Clinical Trials Logo

Nasolacrimal Duct Obstruction clinical trials

View clinical trials related to Nasolacrimal Duct Obstruction.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06346561 Recruiting - Clinical trials for Nasolacrimal Duct Obstruction

The Efficacy of Dexmedetomidine Versus Labetalol In Providing Controlled Hypotension In Dacryocystorhinostomy SurgeryA Comparative Randomized Prospective Study

Start date: March 30, 2024
Phase: N/A
Study type: Interventional

The most important symptoms of nasolacrimal duct obstruction are excessive tearing and mucoid discharge. The proposed treatment in this regard is dacryocystorhinostomy (DCR) surgery. Therefore, hemostasis is of great significance in performing DCR surgery. In this regard, the reduction of controlled hypotension and the control of hemodynamic responses of the body to stress effectively reduce the bleeding volume during surgery. Hence, there is no enough studies about controlled hypotension in DCR we decided to perform such a comparison between the effect of dexmedetomidine and labetalol in providing controlled hypotension during DCR surgery.

NCT ID: NCT06226181 Recruiting - Clinical trials for Nasolacrimal Duct Obstruction

Amniotic Membrane for Dacryocystorhinostomy

AMDCRex
Start date: January 1, 2024
Phase: Phase 1
Study type: Interventional

This study aims to compare the success rate of external dacryocystorhinostomy with and without amniotic membranes in patients with nasolacrimal duct obstruction.

NCT ID: NCT05999630 Recruiting - Thyroid Cancer Clinical Trials

Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer

Start date: August 21, 2023
Phase: Phase 3
Study type: Interventional

The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.